IPX 231
Alternative Names: IPX-231; IPX231-C0001; IPX231-L0007; IPX231-L0012Latest Information Update: 15 May 2018
Price :
$50 *
At a glance
- Originator Impax Pharmaceuticals
- Class Antiparkinsonians
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Parkinson's disease
Most Recent Events
- 07 May 2018 Amneal Pharmaceuticals and Impax Laboratories completed their business combination to form Amneal Pharmaceuticals
- 01 Aug 2014 IPX 231 is available for licensing as of 01 Aug 2014. http://www.impaxlabs.com/our_company/future_directions
- 03 Jun 2014 Impax Pharmaceuticals completes a phase I trial in Parkinson's disease (in volunteers) in Australia (ACTRN12613001057774)